Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Cullinan Therapeutics (Nasdaq: CGEM) announced that CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A., will take part in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 a.m. ET.

A live webcast will be available via the company’s investor relations Events and Presentations page at https://investors.cullinantherapeutics.com/events.

News Market Reaction

-3.89%

1 alert

-3.89% News Effect

-$31M Valuation Impact

$759M Market Cap

0.6x Rel. Volume

On the day this news was published, CGEM declined 3.89%, reflecting a moderate negative market reaction. This price movement removed approximately $31M from the company's valuation, bringing the market cap to $759M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Summit date: February 12, 2026 Event time: 11:00 a.m. ET

2 metrics

Summit date February 12, 2026 Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat

Event time 11:00 a.m. ET Scheduled time for Guggenheim fireside chat

Market Reality Check

Price: $11.83 Vol: Volume 721,129 vs 20-day ...

normal vol

$11.83 Last Close

Volume Volume 721,129 vs 20-day average 685,973 (relative volume 1.05). normal

Technical Price $12.33 trading above 200-day MA at $8.54, near 52-week high of $13.43.

Peers on Argus

CGEM fell 6.66% while close peers were mixed: AUTL up 0.73%, LXRX down 1.55%, PR...

CGEM fell 6.66% while close peers were mixed: AUTL up 0.73%, LXRX down 1.55%, PRTC down 1.6%, VIGL flat, INBX down 3.09%. Moves do not show a unified sector direction.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Corporate update	Positive	+1.8%	Outlined 2026 milestones and highlighted <b>$439.0M</b> cash runway into 2029.
Dec 08	Clinical data update	Positive	+17.5%	Updated Phase 1 CLN-049 AML data with encouraging response rates and safety.
Dec 01	Regulatory designation	Positive	-5.5%	FDA Fast Track designation for CLN-049 in R/R AML and planned ASH presentation.
Nov 20	Regulatory filing	Positive	+3.2%	Initiated rolling NDA for zipalertinib in EGFR ex20ins NSCLC with prior positive data.
Nov 10	Conference participation	Neutral	+3.5%	Announced participation in investor conferences and ASH analyst/investor event.

Pattern Detected

Recent news often saw positive price reactions to clinical and corporate updates, with one notable divergence on FDA Fast Track news.

Recent Company History

Over recent months, CGEM has highlighted key milestones across its pipeline and financial position. A Jan 08 2026 corporate update with 2026 catalysts and $439.0M cash saw a modest gain. Clinical news on CLN-049 and zipalertinib in late 2025 generally aligned with positive moves, while the Dec 01 2025 Fast Track designation drew a negative reaction. Conference participation in Nov 2025 coincided with a small uptick.

Market Pulse Summary

This announcement adds another investor-focused event to Cullinan Therapeutics’ calendar, highlighti...

Analysis

This announcement adds another investor-focused event to Cullinan Therapeutics’ calendar, highlighting continued engagement through a Guggenheim biotech summit fireside chat on February 12, 2026. In recent months, the company communicated substantial clinical and regulatory progress, including CLN-049 data and a rolling NDA for zipalertinib, alongside a reported $439.0M cash position and runway into 2029. Observers may watch for any incremental commentary emerging from the event.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 11:00 a.m. ET.

A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Contacts:

Investors
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com

Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com

FAQ

When will Cullinan Therapeutics (CGEM) present at the Guggenheim Biotech Summit 2026?

Cullinan will present on February 12, 2026 at 11:00 a.m. ET. According to the company, CEO Nadim Ahmed and CMO Jeffrey Jones will participate in a fireside chat and the event is part of the Guggenheim Emerging Outlook: Biotech Summit 2026.

Who from Cullinan Therapeutics (CGEM) will speak at the February 12, 2026 fireside chat?

CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A., will speak. According to the company, both executives will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 11:00 a.m. ET.

How can investors watch Cullinan Therapeutics' (CGEM) fireside chat webcast on February 12, 2026?

The webcast will be available on the company’s investor relations Events and Presentations page. According to the company, viewers can access the live webcast at https://investors.cullinantherapeutics.com/events during or after the February 12, 2026 presentation.

What topics will Cullinan Therapeutics (CGEM) likely cover in the Guggenheim Biotech Summit fireside chat?

The announcement states executives will participate in a fireside chat but does not list topics. According to the company, the session will feature CEO Nadim Ahmed and CMO Jeffrey Jones, suggesting discussion of corporate strategy and clinical-stage programs may be expected.

Is the Cullinan Therapeutics (CGEM) fireside chat at Guggenheim open to the public or investors only?

The company lists a webcast on its investor relations site, implying broad online access. According to the company, the fireside chat will be webcast via the Events and Presentations page, enabling public and investor viewing without specifying registration requirements.

Will Cullinan Therapeutics (CGEM) provide a replay of the February 12, 2026 fireside chat?

A webcast will be available on the investor relations Events and Presentations page, which typically hosts replays. According to the company, the webcast will be posted at https://investors.cullinantherapeutics.com/events for viewing after the live session.